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Over 50% of ST-segment elevation myocardial infarction (STEMI) patients suffer multi-vessel coronary artery disease, which is known to be
associated with worse prognosis. Treatment strategies used in clinical practice vary from acute multi-vessel percutaneous coronary inter-
vention (PCI), through staged PCI procedures to a conservative approach with primary PCI of only the infarct-related artery (IRA) and sub-
sequent medical therapy unless recurrent ischaemia occurs. Each approach has advantages and disadvantages. This review paper summarizes
the international experience and authors’ opinion on this clinically important question. Multi-vessel disease in STEMI is not a single entity and
thus the treatment approach should be individualized. However, the following general rules can be proposed till future large randomized
trials prove otherwise:
(i) Single-vessel acute PCI should be the default strategy (to treat only the IRA during the acute phase of STEMI).
(ii) Acute multi-vessel PCI can be justiﬁed only in exceptional patients with multiple critical (.90%) and potentially unstable lesions.
(iii) Signiﬁcant lesions of the non-infarct arteries should be treated either medically or by staged revascularization procedures—both
options are currently acceptable.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Primary percutaneous coronary intervention (p-PCI) has become
the treatment of choice for patients presenting with ST-segment
elevation myocardial infarction (STEMI) when it can be per-
formed expeditiously by an experienced team.
1–6 The goal is
restoration of ﬂow within 90 min of presentation to a
PCI-equipped centre or within 120 min from the time of the
ﬁrst medical contact.
7,8 This strategy has been found to be
superior to thrombolytic therapy in improving morbidity and
mortality. An important piece of information gained at the
time of angiography and p-PCI is information not only about
the culprit lesion but also about the extent and severity of the
underlying coronary artery disease. In patients presenting with
STEMI, multi-vessel coronary artery disease is found to be
present from 41 to 67% of patients depending upon the baseline
characteristics (especially age) of the speciﬁc population
studied;
9–12 however, in one study only 10% of STEMI patients
initially treated by p-PCI had a clinical indication for non-culprit
PCI during the subsequent follow-up of up to 3 years.
13 The
presence of multi-vessel disease has been found to be associated
with worse prognosis in patients with STEMI.
14 Identiﬁcation of
optimal strategies for treating these patients is the subject of
considerable interest and controversy.
Treatment strategies vary widely from an aggressive approach
which treats all signiﬁcant lesions in the acute phase of p-PCI to
a conservative approach with p-PCI of only the infarct-related
artery (IRA) and subsequent medical therapy unless recurrent
ischaemia occurs. Between these two extremes are other alterna-
tives; mainly that of staged procedures with the IRA treated acutely
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the ﬁrst month following discharge. There is no randomized data
to deﬁnitely answer the issues about the speciﬁc scientiﬁc merits
of any of these approaches. However, there are increasing data
from observational series. Each approach has advantages and disad-
vantages. This review paper summarizes the international experi-
ence and authors’ opinion on this clinically important question.
The authors have not tried to do a formal ‘meta-analysis’ and
rather preferred to describe the current knowledge and to offer
their view on the subject.
Aggressive approach: acute
multi-vessel percutaneous
coronary intervention during
ST-segment elevation myocardial
infarction
The potential advantages of the aggressive approach are complete-
ness of revascularization, treatment of any secondary potentially
unstable lesions, and possible shortening of cumulative hospital
stay. The main disadvantages are increased contrast load (and
thus increased risk of contrast-induced nephropathy), haemo-
dynamic instability in the acute setting, and potentially disastrous
complications of non-infarct artery PCI (Table 1). Several studies
reported promising results with multi-vessel PCI strategy. One
group
15 reported a decrease in recurrent infarctions or ischaemia,
but no survival beneﬁt. Rigattieri et al.
16 found that p-PCI of the
culprit vessel alone with subsequent medical treatment has
better early outcomes, whereas multi-vessel-staged PCI tended
to better long-term outcomes. Another Italian study
17 compared
three different revascularization strategies in 214 consecutive
patients with STEMI and multi-vessel coronary artery disease
undergoing primary angioplasty: culprit vessel angioplasty-only
(COR group); staged revascularization (SR group), and simul-
taneous treatment of non-IRA (CR group). During a mean
follow-up of 2.5 years, at least one major adverse cardiac event
occurred in 50% patients of the COR group, 20% of the SR
group, and 23% of the CR group (P , 0.001).
Another single-centre registry
18 found among 745 p-PCI
patients multi-vessel PCI in STEMI to be feasible and safe. This reg-
istry realistically described the relative proportions of single- (46%)
vs. multi-vessel (54%) disease and the three most frequently used
strategies for multi-vessel disease: p-PCI of the IRA only (39%),
staged PCI (24%), and acute multi-vessel (37%) PCI (Figure 1).
Kong et al.
19 analysed patients undergoing PCI for STEMI in
2000–01 (multi-vessel angioplasty, n ¼ 632 and infarct-related
vessel angioplasty, n ¼ 1350) from the New York State Angio-
plasty Registry database. The highest risk patients (previous myo-
cardial infarction, angioplasty, bypass surgery, or cardiogenic
shock) were excluded. In-hospital mortality was lower (0.8 vs.
2.3%, P ¼ 0.018) in the multi-vessel angioplasty group. No differ-
ences were observed in other ischaemic complications, renal
failure, or length of stay. After multivariate analysis, multi-vessel
angioplasty remained a signiﬁcant predictor of lower in-hospital
death [odds ratio (OR) ¼ 0.27, 95% conﬁdence interval (CI) ¼
0.08–0.90, P ¼ 0.03]. However, 0.8% in-hospital mortality for
STEMI is not realistic and clearly shows, that this retrospective
non-randomized study analysed highly selected, low-risk patients,
and thus results cannot be applied to the routine clinical practice.
................................................................................
Table 1 Acute multi-vessel percutaneous coronary
intervention during ST-segment elevation myocardial
infarction
Advantages Disadvantages
Complete revascularization Increased contrast load/risk of
contrast-induced nephropathy
Treat ischaemia at a distance Radiation exposure
Treat secondary unstable lesions
(plaque instability may not be
limited to the culprit lesion)
Complications of treating
additional lesions may be
potentially fatal
Patient preference/comfort Haemodynamic and general
clinical instability treating
additional lesions
Increased risk of stent thrombosis
in patients with clopidogrel
resistance/intolerance.
Prothrombotic and inﬂammatory
milieu in the acute phase of
STEMI
Coronary spasm may lead to
possible overestimation of
stenosis severity in non-infarct
arteries
Figure 1 The relative proportion of single- vs. multi-vessel
disease and of the three most frequently used PCI (percutaneous
coronary intervention) strategies for multi-vessel disease
(adopted from Corpus et al.
21).
How to treat patients with ST-elevation 397Chen et al.
20 evaluated the outcomes of multi-vessel PCI early
after STEMI. Clinical outcomes were compared between patients
who underwent multi-vessel PCI (n ¼ 239) and patients who
underwent treatment of the IRA alone (n ¼ 1145). The primary
endpoint was cumulative survival at 6, 12, and 36 months. Second-
ary endpoints included a composite of mortality, recurrent infarc-
tion, coronary artery bypass graft, or target vessel revascularization
at the same time points. The multi-vessel PCI group had a signiﬁ-
cantly higher prevalence of adverse prognostic indicators.
Despite this, observed event rates were similar between the
multi-vessel PCI and single-vessel PCI groups. The Kaplan–Meier
estimated 1-year survival was 0.91 (95% CI 0.87–0.95) for the
multi-vessel PCI group and 0.93 (95% CI 0.92–0.95) for the single-
vessel PCI group (P ¼ 0.43). Similarly, 1-year survival free of recur-
rent infarction and target vessel revascularization rates were
similar between the two groups: multi-vessel PCI 0.78 (95% CI
0.73–0.84) and single-vessel PCI 0.78 (95% CI 0.75–0.81).
Conservative approach: acute
percutaneous coronary
intervention of the infarct-related
artery alone (followed by medical
therapy unless recurrent
ischaemia occurs)
Other studies reported better outcomes with a more conservative
strategy of p-PCI only on the IRA in the acute phase (Table 2). The
study of Corpus et al.
21 described signiﬁcantly higher risk of
re-infarction (13.0 vs. 2.8%, P , .001) and even of repeat revascu-
larization (25 vs. 15%, P ¼ 0,007) among 506 patients when treated
by multi-vessel PCI (152 patients) when compared with IRA-only
PCI (354 patients).
The New York State PCI Registry
22 reported that in haemody-
namically stable patients with multi-vessel disease, acute phase
multi-vessel PCI results in an increased in-hospital mortality
(2.4%) when compared with IRA-only PCI (0.9%, P ¼ 0,04). On
the contrary, patients undergoing staged multi-vessel PCI within
60 days after the index procedure had a signiﬁcantly lower
12-month mortality rate than patients undergoing culprit vessel
PCI only (1.3 vs. 3.3%, P ¼ 0.04).
Khattabetal.
23foundnomortalitybeneﬁtfromacutemulti-vessel
PCI.Roeetal.
24describedevenincreasedmortalitywithacutemulti-
vessel PCI strategy and also an increased risk of major adverse
cardiac events with this strategy. The US National Cardiovascular
Data Registry (28 936 STEMI patients) found increased mortality
among 3087 patients with cardiogenic shock when primary multi-
vessel PCI was used
25 and also a trend to increased mortality with
this strategy among all STEMI patients (Figure 2).
Dambrink et al.
26 randomized 121 patients with multi-vessel
disease after p-PCI for STEMI to (i) early fractional ﬂow reserve
(FFR)-guided staged PCI (performed 5–20 days after p-PCI, n ¼
80) vs. (ii) conservative therapy (n ¼ 41). Forty per cent of the non-
culprit lesions did not show haemodynamic signiﬁcance (FFR .
0.75) and subsequent PCI of at least one non-culprit lesion was per-
formed only in 52% of patients in the invasive group. There was no
difference in the left ventricular ejection fraction (EF) at 6 months
(59 vs. 57%, P ¼ 0.362) or in major adverse cardiovascular events
(MACE)(21vs.22%,P ¼ 0.929).Theauthorsconcludedthataninva-
sivestrategytowardsnon-culpritlesionsdoesnotleadtoanincrease
inEForareductioninmajoradverse cardiovascularevents (MACE).
Furthermore,thefunctionalstenosisseverityofnon-culpritlesionsis
frequently overestimated.
The recent meta-analysis of Sethi et al.
27 revealed nine non-
randomized studies (with a total of 4530 patients treated by
acute complete revascularization and 27 323 patients treated by
................................................................................
Table 2 Infarct-related artery culprit lesions alone
then monitor for ischaemia
Advantages Disadvantages
Treat only culprit lesion May leave behind signiﬁcant
ischaemia-producing lesions
Avoid complications associated
with treating other lesions
May not treat other less severe
unstable lesions
The indication for non-infarct
artery PCI can be supported by
the objective evidence for
myocardial ischaemia in regions
supplied by this non-infarct
artery
May not prevent recurrent
ischaemia
The ability to discuss with patients
and their families the relative
risks and beneﬁts of treating
the non-infarct related lesion
vs. continued medical therapy
or surgical options
Patients have to return to
laboratory routinely
Figure 2 In-hospital mortality after multi-vessel vs. single-
vessel percutaneous coronary intervention in STEMI
(ST-elevation myocardial infarction) from the US National
Cardiovascular Data Registry (adopted from Chen et al.
20).
P. Widimsky and D.R. Holmes Jr 398the IRA PCI in the acute phase) and two small randomized studies.
Major adverse cardiovascular events (OR ¼ 0.95, 95% CI 0.47–
1.90) and long-term mortality (OR ¼ 1.10, 95% CI 0.76–1.59)
were similar for both strategies.
Also one small single-centre retrospective study of Mohamad
et al.
28 concluded that intervention of non-critical lesions did not
seemtoimproveMACEsorall-causemortalityat1yearoffollow-up
and might in fact have had a detrimental effect on outcomes.
A recently published secondary analysis of the APEX-acute
myocardial infarction trial
12 found non-IRA PCI to be performed
only in 9.9% of patients with STEMI and multi-vessel disease.
Ninety-day death and death/congestive heart failure/shock were
higher in this non-IRA group compared with the IRA-only PCI
group (12.5 vs. 5.6%, P ,0.001 and 17.4 vs. 12.0%, P , 0.020,
respectively). After adjusting for patient and procedural character-
istics as well as propensity for performing non-IRA PCI, this
procedure remained independently associated with an increased
hazard of 90-day mortality [adjusted hazard ratio 2.44, 95% CI
(1.55–3.83), P ,0.001].
Intermediate approach: acute
percutaneous coronary
intervention of the infarct-related
artery followed by staged
percutaneous coronary
intervention of secondary lesions
The SWISSI II randomized trial
29 found elective (non-acute) PCI to
be superior to medical therapy for patients with proven silent
myocardial ischaemia after STEMI (Figure 3; Table 3).
There are no published large randomized trials. We found only
ﬁve small randomized studies,
17,26,30–32 enrolling between 69 and
219 patients per study. These studies have signiﬁcant limitations,
the main being extremely low mortality (1.9% short-term and
3.8% long-term), which may reﬂect the high degree of pre-
selection with high-risk STEMI patients being excluded. Four of
these ﬁve randomized trials reported short-term mortality of
STEMI patients between 0% (two studies) and 1.4%. Thus, their
results may not be applicable to routine clinical practice. One
small randomized study
33 compared multi-vessel PCI vs. culprit
vessel only PCI in a small mixed group of patients including patients
without previous acute myocardial infarction.
Advantages and disadvantages of
multi-vessel percutaneous coronary
intervention in ST-segment
elevation myocardial infarction
The summary of all above-mentioned trials and registries is in
Table 4. The reasons supporting multi-vessel PCI in STEMI patients
and arguments against this strategy were summarized by
Kornowski
34:
Reasons supporting multi-vessel PCI include:
(i) Plaque instability may not be limited to the culprit lesion,
35 but
may rather involve larger areas of the coronary tree (systemic
endothelial dysfunction and higher platelet activity in acute
coronary syndromes).
Figure 3 The SWISSI II randomized trial. Kaplan–Meier survivor function for cardiac death, non-fatal myocardial infarction, and symptom-
driven revascularization. From Erne et al.
29 Permission for publication granted.
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Table 3 Infarct-related artery culprit lesions then
staged secondary lesions
Advantages Disadvantages
Optimize potential for complete
revascularization
Economics
PCI of a stable stenosis might be
intervened more safelyat a later
phase, after stabilization
May treat asymptomatic lesions
Complications of treating
secondary lesions early after
index event
Timing uncertain
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Table 4 The published studies comparing multi-vessel percutaneous coronary intervention in AMI vs. single
(infarct-related artery)-vessel percutaneous coronary intervention
First author
(reference number)
Number of patients in
multi-vessel PCI group
Number of patients in
single-vessel PCI group
Main results
Randomized studies
Ijsselmuiden
31 108 111 No difference in MACE rates at 1 month (14.4 vs. 9.3%), 1 year
(32.4 vs. 26.9%), and 4.6 years (40.4 vs. 34.6%). Study
conclusion: the decision of whether to perform culprit vessel
or complete revascularization can be made on an individual
basis.
Politi
17 130 84 Multi-vessel PCI decreased in-hospital death, repeat
revascularisation, and rehospitalization (all P , 0.05).
Dambrink
26 80 41 No difference in ejection fraction or in MACE. The stenosis
severity of non-culprit lesions is frequently overestimated.
Ochala
32 92 (this study compared acute
multi-vessel PCI vs. staged
multi-vessel PCI)
0 (no such group in this
study)
No difference in MACE. This study had too many exclusion
criteria (STEMI mortality 0% in both groups!) to be relevant
for clinical practice.
Di Mario
30 52 17 Multi-vessel PCI increased the duration of the procedure (69 vs.
53 min, P ¼ 0.032) and the contrast load (341 vs. 242 mL,
P ¼ 0.025). Not signiﬁcantly increased the in-hospital major
adverse cardiac events (3.8 vs. 0%, P ¼ 0.164).
Non-randomized registries
Cavender
25 3134 25 802 Multi-vessel PCI increased in-hospital mortality (7.9 vs. 5.1%,
P , 0.01), including patients with cardiogenic shock (36.5 vs.
27.8%; adjusted OR 1.54, 95% conﬁdence interval 1.22–
1.95).
Hannan
22 797 2724 After exclusion of cardiogenic shock patients, multi-vessel PCI
increased in-hospital mortality (2.4 vs. 0.9%, P ¼ 0.04). Staged
multi-vessel PCI within 60 days decreased 1-year mortality
(1.3 vs. 3.3%, P ¼ 0.04).
Toma
12 217 1984 Multi-vessel PCI associated with an increased hazard of 90-day
mortality [adjusted HR 2.44, 95% CI (1.55–3.83), P , 0.001].
Kong
19 632 1350 Multi-vessel PCI decreased in-hospital death (OR ¼ 0.27, 95%
conﬁdence interval ¼ 0.08–0.90, P ¼ 0.03).
Chen
20 239 1145 No difference in mortality or combined death, myocardial
infarction, coronary artery bypass graft, or target vessel
revascularization.
Corpus
21 152 354 Multi-vessel PCI increased re-infarction (13.0 vs. 2.8%,
P , 0.001), revascularization (25 vs. 15%, P ¼ 0.007), and
MACEs (40 vs. 28%, P ¼ 0.006) at 1 year (OR ¼ 1.67,
P ¼ 0.01).
Varani
18 243 159 After exclusion of cardiogenic shock patients, multi-vessel PCI
decreased 30-day mortality (2.8 vs. 6.3%, P ¼ 0.023).
Roe
24 79 79 Multi-vessel PCI increased non-signiﬁcantly the risk of death (25
vs. 16.4%, n.s.), re-infarction (8.8 vs. 1.6%, P , 0.07) and
signiﬁcantly the risk of stroke (10.3 vs. 0%, P , 0.01) at
6-month follow-up.
Qarawani
15 95 25 Multi-vessel PCI decreased major cardiac events (recurrent
ischaemia, re-infarction, acute heart failure, and in-hospital
mortality 16.7 vs. 52%, P ¼ 0.0001).
Rigattieri
16 64 46 Multi-vessel PCI non-signiﬁcantly increased in-hospital MACE
(20.3 vs. 10.8%, P ¼ 0.186); but decreased out of hospital
MACE (9.3 vs. 23.9%, P ¼ 0.037). Periprocedural myocardial
infarction after the elective procedure occurred in 15.6% of
patients.
Khattab
23 28 45 No difference in major adverse cardiac events at 1 year (24 vs.
28%, P ¼ 0.73).
Mohamad
28 34 29 No difference (a trend for better outcomes in IRA PCI only).
P. Widimsky and D.R. Holmes Jr 400(ii) Complete coronary revascularization is known to be associated
with better long-term prognosis.
(iii) Patient preference: patients may feel more comfortable when
going home ‘after complete repair’. Our experience repeat-
edly showed, that when we recommend medical therapy to
patients with multi-vessel disease after successful p-PCI of
the IRA, some patients seek second opinion in other
cardiac centres and undergo a second PCI there.....
Kornowski found more reasons against acute multi-vessel PCI:
(i) The acute phase of STEMI is a highly unstable condition
(haemodynamic instability, heart failure, arrhythmias, resusci-
tation, and patient stress among others) and is thus certainly
not an ideal situation to perform PCI of a stable stenosis,
which might be intervened in probably more safely at a
later phase, after stabilization.
(ii) The acute phase of STEMI is an extremely prothrombotic and
inﬂammatory milieu, which contributes to the potentially
higher risk of additional PCI.
(iii) Some degree of diffuse coronary spasm (either due to endo-
thelial dysfunction or due to catecholamine use) is frequently
presentintheacutephaseofSTEMI,whichmayleadtopossible
overestimation of stenosis severity in non-infarct arteries.
36
(iv) The decision to perform non-infarct artery PCI in the acute
phase of STEMI is usually not supported by the objective evi-
dence for myocardial ischaemia in regions supplied by this
non-infarct artery. It is thus the classical ‘occulo-stenotic’ indi-
cation and not evidence-based indication for PCI.
(v) Multi-vessel PCI increases the contrast overload and further
increases (already high) risk of contrast-induced nephropathy.
(vi) Any potential PCI complications in the non-infarct artery may
lead to catastrophic consequences (double myocardial jeo-
pardy) including periprocedural death.
(vii) Thelimitedabilitytodiscusswithpatientsandtheirfamiliesthe
relative risks and beneﬁts of treating the non-infarct-related
lesion vs. continued medical therapy or surgical options.
From literature review to real life:
extreme variation of different
clinical and angiographic
scenarios!
The main limitation of all the above-mentioned published papers is
the simpliﬁcation. Patients with multi-vessel disease are divided
into two groups: those treated by acute or staged multi-vessel
PCI and those not treated by this strategy. The every day real-life
clinical practice brings much more different clinical scenarios. The
decision to proceed with multi-vessel PCI is simple in the rare
( 1% of all p-PCIs) situation when two unstable (thrombus con-
taining) IRA can be clearly demonstrated by the acute phase cor-
onary angiography. This is the only situation, when there is
almost no doubt about the PCI strategy (the only doubt is which
artery should be dilated ﬁrst). However, in the vast majority of
p-PCIs, a single IRA can be easily recognized and treated.
Thereare  60possiblescenariosbasedoncombinationsofangio-
graphic(numberofdiseasedvessels,lesionseverity,locationandtype,
chronic total occlusions, thrombolysis in myocardial infarction ﬂow,
collaterals, wall motion in the supplied territory, etc.) and clinical
(Killip class, immediate post-PCI haemodynamic situation, renal func-
tion, etc.) ﬁndings in individual patients. Clinical decision-making in
this situation is thus really complex and should be always individua-
lized. It is unlikely that any randomized clinical trial in the future can
be able to fully address this complexity and thus, experienced, wise
clinical judgement will probably remain the most important factor
in this difﬁcult situation.
Functional (exercise stress) testing along with the clinical picture
(patients’ symptoms) should be an important part of the decision-
making algorithm. Patients who are asymptomatic and have nega-
tive functional tests and no evidence for silent ischaemia after
their ﬁrst STEMI should currently be treated conservatively.
Theroleofcoronarybypasssurgery(CABG)inpatientswithmulti-
vessel disease after STEMI was never investigated in a randomized
study; however, it is a routine part of the clinical decision making.
There is no uniform agreement on the CABG indications after
STEMI treated by p-PCI. In most centres, once the culprit artery
was treated by PCI, the other stenosed coronary arteries are either
revascularized by staged PCI or are treated conservatively.
However, in speciﬁc situations (e.g. triple-vessel disease with left
mainstenosis,anatomynotsuitableforPCI,diabeteswithtriple-vessel
disease, etc.), CABG should remain an important part of the treat-
ment algorithm. Obviously, the indication for CABG should be sup-
portedbyresidualischaemia(spontaneousorprovoked)afterSTEMI.
What do the guidelines
recommend?
The European Society of Cardiology guidelines for PCI
37 state that
in multi-vessel disease, p-PCI should be directed only at the
infarct-related coronary artery. Decisions about PCI of non-culprit
lesions should be done later and guided by objective evidence of
residual ischaemia. Only in the setting of cardiogenic shock is
there a consensus for attempting multi-vessel PCI in selected
patients with multiple critical lesions.
A2009reportontheappropriatenesscriteriaforcoronaryrevascu-
larization written by the expert panel of the ACCF/SCAI/STS/AATS/
AHA/ASNC
38 considers revascularization of a non-IRA during index
hospitalization inappropriate in STEMI patients with successful treat-
mentofthe culprit arteryby p-PCIorﬁbrinolysis when these patients
areasymptomatic,withoutheartfailure,havenoevidenceofrecurrent
or provocable ischaemia or did not have any unstable ventricular
arrhythmias during the index hospitalization and have normal EF. On
the other hand, STEMI or non-STEMI myocardial infarction patients
aftersuccessfulPCIofculpritarterywithsymptomsofrecurrentmyo-
cardial ischaemia and/or high-risk ﬁndings on non-invasive stress
testing performed after index hospitalization are suitable candidates
for revascularization of additional coronary arteries.
Currently running/future trials
Several studies are currently running trying to contribute
to this question. One such study is led by D. Wood
How to treat patients with ST-elevation 401(http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01065103), and
another by O. Hlinomaz, and L. Groch (the PRAGUE-13 study).
None of these is large enough to provide a deﬁnite answer. The
authors are not currently aware about a larger ongoing study on
this topic.
Conclusions
Multi-vessel disease in STEMI is not a single entity and thus the
treatment approach should be individualized. However, the follow-
ing general rules
39 can be proposed till future large randomized
trials prove otherwise:
(i) Single-vessel acute PCI should be the default strategy (to treat
only the IRA during the acute phase of STEMI).
(ii) Acute multi-vessel PCI can be justiﬁed only in haemodynami-
cally unstable patients with multiple truly critical (.90%)
lesions.
(iii) Signiﬁcant lesions of the non-culprit arteries should be
treated either medically or by staged revascularization pro-
cedures—both options are currently acceptable.
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